Vascular Aging Research Study
Researchers at The University of Missouri are conducting a study to help determine if a medicine called empagliflozin can help older adults’ blood vessels stay healthier.
Fast Facts
Ages 60-80
No Diabetes or Heart Diseases
Compensation Provided
Conducted in Columbia, MO
Survey Background
This research study at the University of Missouri looks at whether a medicine called empagliflozin can improve the health of blood vessels in older adults. As people age, their blood vessels can become stiffer, which may lead to heart and kidney problems.
Empagliflozin, also called Jardiance, is currently used as a medication for the treatment of diabetes. This study includes an off-label use of this medication to better understand its effects on blood vessels.
We are recruiting individuals with a BMI<45kg/m2 and no known history of diabetes or heart disease. Eligible participants will complete a screening visit and 6 additional study visits at the University of Missouri.
Help us learn more about aging! Join our study today.
Survey Background
This research study at the University of Missouri looks at whether a medicine called empagliflozin can improve the health of blood vessels in older adults. As people age, their blood vessels can become stiffer, which may lead to heart and kidney problems.
Empagliflozin, also called Jardiance, is currently used as a medication for the treatment of diabetes. This study includes an off-label use of this medication to better understand its effects on blood vessels.
We are recruiting non-tobacco using individuals with BMI≤40kg/m2 and no known history of heart disease. Eligible participants will complete a screening visit and 6 additional study visits at the University of Missouri.
Help us learn more about hypertension! Join our study today.
Additional Information
The purpose of this clinical trial is to see if a medication called empagliflozin can affect blood vessel health in adults ages 60-80.
You may qualify for this survey if you meet the following criteria:
- Ages 60-80
- BMI < 45
- No heart disease diagnosis
- No diabetes diagnosis
If you are eligible and choose to participate in the research study, you will complete:
- A 2-hour screening visit
- Two 30-minute equipment fittings
- Two 2-hour follow-ups
- Two 4-hour assessments
- 12 weeks of home medication/placebo administration
All study visits will occur at the University of Missouri’s Clinical Translational Science Unit (CTSU).
You will receive up to $600 in compensation for your participation in the study.
There is no cost for you to participate in our research study.